Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free ABUS Stock Alerts

Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume

Arbutus Biopharma logo
$5.09 +0.01 (+0.20%)
Closing price 09/1/2026 04:00 PM Eastern
Extended Trading
$5.22 +0.13 (+2.51%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Arbutus Biopharma Short Interest Overview

As of August 14, 2026, Arbutus Biopharma (ABUS) had a short interest of 18.46 million shares sold short, representing 11.65% of the public float. This marks a -8.80% decrease in short interest since the prior report. The short interest ratio (days to cover) is 15.1, meaning it would take 15.1 days of the average trading volume of 4.01 million shares to cover all short positions.

Current Short Interest
18,456,085 shares
Previous Short Interest
20,236,241 shares
Change Vs. Previous Month
-8.80%
Dollar Volume Sold Short
$86.19 million
Short Interest Ratio
15.1 Days to Cover
Last Record Date
August 14, 2026
Outstanding Shares
198,106,000 shares
Short Percent of Float
11.65%
Today's Trading Volume
2,609,638 shares
Average Trading Volume
4,006,972 shares
Today's Volume Vs. Average
65%
Short Selling Arbutus Biopharma?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Arbutus Biopharma and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

ABUS Short Interest Over Time

ABUS Days to Cover Over Time

ABUS Percentage of Float Shorted Over Time

Arbutus Biopharma Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/14/202618,456,085 shares $86.19 million -8.8%11.6%15.1 $4.67
7/31/202620,236,241 shares $87.83 million +3.0%12.8%13.69 $4.34
7/15/202619,653,287 shares $89.62 million +14.9%12.4%7.4 $4.56
6/30/202617,111,453 shares $82.13 million -2.4%10.8%4.89 $4.80
6/15/202617,522,670 shares $75.70 million +3.2%11.1%13.96 $4.32
5/29/202616,982,764 shares $77.44 million +3.3%10.7%9.18 $4.56
5/15/202616,438,082 shares $69.70 million -7.4%10.4%17.08 $4.24
4/30/202617,743,389 shares $74.52 million -0.3%11.2%7.17 $4.20
4/15/202617,803,913 shares $79.76 million +10.1%11.3%11.44 $4.48
3/31/202616,174,093 shares $72.78 million -1.4%10.2%7.04 $4.50
3/13/202616,405,599 shares $69.89 million +11.2%10.7%4.18 $4.26
2/27/202614,756,509 shares $68.77 million -1.6%9.3%9.52 $4.66
2/13/202614,998,521 shares $59.69 million +10.6%9.5%6.43 $3.98
1/30/202613,558,940 shares $56.00 million +3.8%8.8%7.47 $4.13
1/15/202613,067,041 shares $61.42 million +4.2%8.5%12.17 $4.70
12/31/202512,535,638 shares $60.30 million +16.7%8.2%8.63 $4.81
12/15/202510,740,954 shares $53.17 million -4.2%7.0%9.28 $4.95
11/28/202511,206,745 shares $49.37 million +6.1%7.3%9.87 $4.41
11/14/202510,563,698 shares $47.75 million +6.5%6.9%10.74 $4.52
10/31/20259,916,540 shares $46.91 million +0.5%6.5%10.35 $4.73
10/15/20259,860,000 shares $44.07 million -2.8%6.5%9.1 $4.47
9/30/202510,140,000 shares $46.04 million -9.1%N/A9.7 $4.54
9/15/202511,160,000 shares $50.55 million +5.8%N/A10.4 $4.53
8/31/202510,550,000 shares $39.14 million -15.7%6.9%11.5 $3.71
8/15/202512,510,000 shares $42.16 million -3.6%N/A16.1 $3.37
7/31/202512,980,000 shares $42.57 million -4.8%8.5%17.1 $3.28
7/15/202513,640,000 shares $42.69 million -0.9%N/A17.2 $3.13
6/30/202513,770,000 shares $42.55 million +7.2%9.0%15.5 $3.09
6/15/202512,840,000 shares $45.33 million +0.7%8.4%13.8 $3.53
5/31/202512,750,000 shares $42.84 million +10.9%7.0%13.5 $3.36
5/15/202511,500,000 shares $35.88 million +2.8%6.3%10.7 $3.12
4/30/202511,190,000 shares $39.72 million +1.3%N/A10.9 $3.55
4/15/202511,050,000 shares $34.92 million +12.2%6.1%11.1 $3.16
3/31/20259,850,000 shares $34.38 million +2.9%5.4%10.1 $3.49
3/15/20259,570,000 shares $31.58 million +13.8%5.3%10.9 $3.30
2/28/20258,410,000 shares $29.01 million +16.6%4.6%9.8 $3.45
2/15/20257,210,000 shares $23.72 million +7.3%4.0%8.8 $3.29
1/31/20256,720,000 shares $22.38 million +1.2%N/A8.1 $3.33
1/15/20256,640,000 shares $21.78 million +11.6%N/A8 $3.28
12/31/20245,950,000 shares $19.46 million -0.3%N/A6.8 $3.27
Here’s the stock symbol I’ve promised (Ad)

Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel

Get the stock name and ticker symbol free of charge today
12/15/20245,970,000 shares $20.78 million +2.6%N/A6.9 $3.48
11/30/20245,820,000 shares $20.14 million -4.0%N/A5.7 $3.46
11/15/20246,060,000 shares $22.06 million -7.3%N/A5.3 $3.64
10/31/20246,540,000 shares $25.15 million -16.1%N/A5.9 $3.85
10/15/20247,790,000 shares $32.02 million +5.8%N/A6.9 $4.11
9/30/20247,360,000 shares $28.34 million +12.2%N/A6.6 $3.85
9/15/20246,560,000 shares $29.32 million +8.3%N/A5.6 $4.47
8/31/20246,060,000 shares $23.45 million -8.7%N/A5.8 $3.87
8/15/20246,640,000 shares $24.90 million -2.4%N/A6.6 $3.75
7/31/20246,800,000 shares $25.64 million -3.1%N/A6.8 $3.77
7/15/20247,020,000 shares $26.33 million +16.8%N/A7.3 $3.75
6/30/20246,010,000 shares $18.57 million +11.9%N/A6.1 $3.09
6/15/20245,370,000 shares $16.86 million +6.8%N/A4.2 $3.14
5/31/20245,030,000 shares $16.90 million -5.8%N/A4.1 $3.36
5/15/20245,340,000 shares $15.01 million -8.1%N/A4.6 $2.81
4/30/20245,810,000 shares $15.86 million +12.4%N/A4.3 $2.73
4/15/20245,170,000 shares $15.35 million +13.6%N/A3.7 $2.97
3/31/20244,550,000 shares $11.74 million +10.2%N/A3.4 $2.58
3/15/20244,130,000 shares $10.82 million +1.5%N/A4.4 $2.62
2/29/20244,070,000 shares $11.40 million +10.3%N/A4.2 $2.80
2/15/20243,690,000 shares $10.74 million -39.7%N/A3.8 $2.91
1/31/20246,120,000 shares $14.50 million -4.8%N/A7.3 $2.37
1/15/20246,430,000 shares $14.85 million +3.4%N/A9.5 $2.31
12/31/20236,220,000 shares $15.55 million +0.5%N/A9.1 $2.50
12/15/20236,190,000 shares $13.87 million +0.2%N/A9.2 $2.24
11/30/20236,180,000 shares $12.67 million -8.2%N/A9.4 $2.05
11/15/20236,730,000 shares $12.38 million +6.7%N/A10.6 $1.84
10/31/20236,310,000 shares $11.55 million +9.4%N/A10.4 $1.83
10/15/20235,770,000 shares $10.73 million -16.1%N/A9.4 $1.86
9/30/20236,880,000 shares $13.97 million +18.6%N/A11.2 $2.03
9/15/20235,800,000 shares $11.83 million +12.0%N/A9.4 $2.04
8/31/20235,180,000 shares $10.52 million +0.8%N/A8.3 $2.03
8/15/20235,140,000 shares $10.23 million +5.1%N/A8.4 $1.99
7/31/20234,890,000 shares $10.61 million +0.8%N/A8.5 $2.17
7/15/20234,850,000 shares $10.82 million -0.8%N/A7.8 $2.23
6/30/20234,890,000 shares $11.25 million +12.7%N/A6.8 $2.30
6/15/20234,340,000 shares $10.59 million +2.1%N/A5.8 $2.44
5/31/20234,250,000 shares $10.58 million -0.9%N/A5.3 $2.49
5/15/20234,290,000 shares $10.98 million +8.3%N/A4.7 $2.56
4/30/20233,960,000 shares $9.94 million -7.0%N/A4.2 $2.51
4/15/20234,260,000 shares $12.23 million -13.9%N/A4.7 $2.87
3/31/20234,950,000 shares $15.00 million +5.5%N/A5.4 $3.03
3/15/20234,690,000 shares $14.21 million +15.8%N/A5 $3.03
2/28/20234,050,000 shares $11.26 million +1.5%N/A4.5 $2.78
2/15/20233,990,000 shares $10.85 million -7.4%N/A4.5 $2.72
1/31/20234,310,000 shares $12.97 million -8.5%N/A4.6 $3.01
1/15/20234,710,000 shares $13.42 million -0.6%N/A4.9 $2.85
12/30/20224,740,000 shares $11.04 million +23.1%N/A4.6 $2.33
12/15/20223,850,000 shares $10.43 million -4.0%N/A4.1 $2.71
11/30/20224,010,000 shares $9.42 million +7.2%N/A4.4 $2.35
Bezos… DOOMED (Ad)

A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel

Watch James Altucher's free video breakdown before the September 25 deadline.
11/15/20223,740,000 shares $10.43 million -10.3%N/A4.3 $2.79
10/31/20224,170,000 shares $9.76 million -0.7%N/A5.2 $2.34
10/15/20224,200,000 shares $9.20 million +2.2%N/A5.4 $2.19
9/30/20224,110,000 shares $7.85 million +7.6%N/A5.6 $1.91
9/15/20223,820,000 shares $8.82 million -2.6%N/A4.7 $2.31
8/31/20223,920,000 shares $8.70 million -11.1%N/A4.7 $2.22
8/15/20224,410,000 shares $11.16 million -7.4%N/A4.8 $2.53
7/31/20224,760,000 shares $11.00 million -7.4%N/A4.5 $2.31
7/15/20225,140,000 shares $13.06 million -2.5%N/A4.8 $2.54
6/30/20225,270,000 shares $14.28 million +7.1%N/A4.5 $2.71
6/15/20224,920,000 shares $12.55 million -7.9%N/A3.9 $2.55
5/31/20225,340,000 shares $12.98 million +6.6%N/A3.8 $2.43
5/15/20225,010,000 shares $11.57 million -5.8%N/A2.9 $2.31
4/30/20225,320,000 shares $12.40 million -8.3%N/A2.9 $2.33
4/15/20225,800,000 shares $15.95 million -12.8%N/A2.6 $2.75
3/31/20226,650,000 shares $19.82 million +0.3%N/A2.7 $2.98
3/15/20226,630,000 shares $18.96 million -8.8%N/A2.3 $2.86
2/28/20227,270,000 shares $23.26 million +3.0%N/A1.8 $3.20
2/15/20227,060,000 shares $22.95 million +4.1%N/A0.7 $3.25
1/31/20226,780,000 shares $19.05 million +73.0%N/A0.7 $2.81
1/15/20223,920,000 shares $12.98 million -13.9%N/A0.4 $3.31
12/31/20214,550,000 shares $17.70 million -43.6%N/A0.5 $3.89
12/15/20218,060,000 shares $32.97 million +253.5%N/A0.8 $4.09
11/30/20212,280,000 shares $7.30 million -4.2%N/A0.2 $3.20
11/15/20212,380,000 shares $8.00 million -15.0%N/A1 $3.36
10/29/20212,800,000 shares $11.28 million +0.7%N/A1.1 $4.03
10/15/20212,780,000 shares $11.34 million No Change3.5%1.1 $4.08
9/30/20212,780,000 shares $11.93 million -24.9%3.5%1.2 $4.29
9/15/20213,700,000 shares $15.61 million -6.1%4.6%1.6 $4.22

ABUS Short Interest - Frequently Asked Questions

Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been covered or closed out. As of August 14th, traders have sold 18,456,085 shares of ABUS short. 11.65% of Arbutus Biopharma's shares are currently sold short. Learn More on Arbutus Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 15.1. Learn More on Arbutus Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.65% of Arbutus Biopharma's floating shares are currently sold short.

Arbutus Biopharma saw a drop in short interest in August. As of August 14th, there was short interest totaling 18,456,085 shares, a drop of 8.8% from the previous total of 20,236,241 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

11.65% of Arbutus Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Arbutus Biopharma: Legend Biotech Corporation Sponsored ADR (9.60%), Tango Therapeutics, Inc. (27.39%), Denali Therapeutics Inc. (12.44%), Viking Therapeutics, Inc. (20.17%), Arcus Biosciences, Inc. (11.77%), Telix Pharmaceuticals Limited (0.07%), Iovance Biotherapeutics, Inc. (24.65%), GRAIL, Inc. (18.60%), IDEAYA Biosciences, Inc. (12.42%), AbCellera Biologics Inc. (18.83%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($71.57 billion), Invesco QQQ ($46.97 billion), iShares Russell 2000 ETF ($24.02 billion), Nebius Group N.V. ($15.37 billion), Sandisk Corporation ($12.60 billion), SPDR S&P Biotech ETF ($12.14 billion), Western Digital Corporation ($10.32 billion), iShares 20+ Year Treasury Bond ETF ($8.38 billion), VanEck Semiconductor ETF ($7.62 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($7.07 billion). View all of the most shorted stocks.

Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is August, 14 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like ABUS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:ABUS is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/25/2026. FINRA publishes updated short interest twice a month.
From Our Partners
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Buy this stock tomorrow morning
A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...
Stansberry Research | Sponsoredtc pixel